Q1 2026 Psychedelic Drug Development Pipeline: Bullseye Charts By Watertime - February 19, 2026 7 Q1 2026 BULLSEYE CHARTS This resource is supported by Learn More UBC partners with biopharma to modernize evidence… Source RELATED ARTICLESMORE FROM AUTHOR A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites
